Latest News - Nicox

Friday, November 03, 2017 | Earnings & Financials, Glaucoma, Nicox

Nicox Highlights Vyzulta Approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives

Nicox highlighted recent regulatory progress, with the approval in the United States of its partnered product, Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), and provided an overview of th…

Read the full story

Thursday, November 02, 2017 | FDA Approval/Clearance, Bausch+Lomb, Nicox , Valeant

Bausch + Lomb And Nicox Announce FDA Approval of Glaucoma Treatment Vyzulta

Bausch + Lomb and Nicox announced that the FDA has approved Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), indicated for the reduction of IOP in patients with open-angle glaucoma or o…

Read the full story

Tuesday, October 24, 2017 | Earnings & Financials, Nicox

Nicox Provides Update on Zerviate and Ophthalmic Pipeline

Nicox SA provided an update on its activities and cash balance as of September 30, 2017. Earlier this month, Nicox entered into two collaborations to explore the potential for sustained-release for…

Read the full story

Friday, October 20, 2017 | Glaucoma, Partnerships, Nicox

Nicox Enters Research Collaboration with Re-Vana Therapeutics to Explore Drug Delivery Platform for the Reduction of IOP

Nicox SA and Re-Vana Therapeutics announced that they have entered into a research collaboration to explore combining Nicox’s next generation of stand-alone nitric oxide (NO)-donors with Re-Vana…

Read the full story

Tuesday, October 10, 2017 | Glaucoma, Partnerships, Nicox , Psivida

Nicox and pSivida Enter Strategic Collaboration Agreement to Develop Sustained-Release Drug to Lower Intraocular Pressure in Patients with Glaucoma

Nicox and pSivida announced their entry into a collaboration agreement to explore the potential of combining Nicox's nitric oxide (NO)-donating compounds with pSivida's bioerodible sustained-r…

Read the full story

Thursday, September 21, 2017 | Partnerships, Nicox

Nicox Announces Licensing Agreement With Eyevance for Commercialization of Zerviate in the United States

Nicox has entered into an exclusive licensing agreement with Eyevance Pharmaceuticals for the commercialization of Zerviate (cetirizine ophthalmic solution) 0.24% in the United States. Under the te…

Read the full story

Wednesday, May 31, 2017 | FDA Approval/Clearance, Nicox

Nicox Receives FDA Approval of Allergic Conjunctivitis Treatment Zerviate

Nicox announced that the FDA has approved the new drug application for Zerviate (cetirizine ophthalmic solution 0.24%; formerly AC-170), the first topical ocular formulation of the antihistamine cetir…

Read the full story

Tuesday, April 11, 2017 | Clinical Trials, Nicox

Nicox Announces PDUFA Date for Allergic Conjunctivitis Drug Candidate Zerviate

Nicox announced that the FDA has set a PDUFA date of September 8, 2017 for its decision on the new drug application (NDA) for Zerviate (cetirizine ophthalmic solution) 0.24%, Nicox's novel, propri…

Read the full story

Tuesday, March 21, 2017 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb and Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

Bausch + Lomb and Nicox announced that the FDA has set a deadline of August 24, 2017 for its decision on the new drug application for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene b…

Read the full story

Thursday, March 09, 2017 | Clinical Trials, Nicox

Nicox Resubmits AC-170 (Zerviate) NDA for Allergic Conjunctivitis Drug Candidate

Nicox announced the resubmission of the new drug application (NDA) for AC-170, its novel, proprietary, cetirizine eye drop formulation for the treatment of ocular itching associated with allergic conj…

Read the full story

Monday, February 27, 2017 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb And Nicox Resubmit FDA New Drug Application For Glaucoma Candidate Latanoprostene Bunod

Bausch + Lomb and Nicox announced the resubmission of a new drug application (NDA) to the FDA seeking approval for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene bunod is an IOP-lowe…

Read the full story

Tuesday, February 21, 2017 | Clinical Trials, Nicox

Nicox Presents NCX 667 Scientific Data at AOPT 2017

Nicox SA announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientif…

Read the full story

Tuesday, January 24, 2017 | Clinical Trials, Nicox

Nicox Provides Clinical and Regulatory Update for NCX 470 for IOP Lowering

Nicox provided certain regulatory and clinical updates for NCX 470, its novel nitric oxide (NO) donating bimatoprost analog being developed for IOP lowering. Nicox held a preinvestigational new dru…

Read the full story

Thursday, January 05, 2017 | Clinical Trials, Nicox

Nicox Provides Clinical and Regulatory Update for NCX 4251 in Blepharitis

Nicox S.A. provided certain regulatory and clinical updates for NCX 4251, its novel ophthalmic suspension of fluticasone propionate nanocrystals being developed for the first time as a topical treatme…

Read the full story

Wednesday, November 09, 2016 | Miscellaneous, Bausch+Lomb, Nicox , Valeant

Nicox Provides Update on Latanoprostene Bunod and AC-170

Nicox SA provided an update on the regulatory status of its key projects, latanoprostene bunod and AC-170. Valeant Pharmaceuticals has stated that Nicox's licensee for latanoprostene bunod, Bau…

Read the full story
Load More